TAIPEI, June 22, 2026 /PRNewswire/ -- AnHorn Medicines today announced that its lead neuroprotective candidate AH-008, being developed for the prevention of chemotherapy-induced peripheral neuropathy (CIPN), has achieved two major regulatory milestones: Investigational New Drug (IND)...
Hence then, the article about ah 008 achieves dual regulatory milestones with u s fda ind clearance and taiwan cde index case designation was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( AH-008 Achieves Dual Regulatory Milestones with U.S. FDA IND Clearance and Taiwan CDE Index Case Designation )
Also on site :
- TVLine Asks: Did You Catch Ted Lasso/Severance Crossover? Does DWTS Pro Make You Feel Old? Who's Trying To Contact Stuart? And More!
- Trump says he only talks to his children to say ‘I love you’ not about his billion-dollar crypto businesses
- Ariana Grande Celebrates End of N. American Eternal Sunshine Leg, Says She’s ‘Overwhelmed With Love and the Deepest Gratitude’